Vaccinations

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00306-8/fulltext

The COVID-19 pandemic is unlikely to end until there is global roll-out of vaccines that protect against severe disease and preferably drive herd immunity. Regulators in numerous countries have authorised or approved COVID-19 vaccines for human use, with more expected to be licensed in 2021. Yet having licensed vaccines is not enough to achieve global control of COVID-19: they also need to be produced at scale, priced affordably, allocated globally so that they are available where needed, and widely deployed in local communities.

In this Health Policy paper, we review potential challenges to success in each of these dimensions and discuss policy implications. To guide our review, we developed a dashboard to highlight key characteristics of 26 leading vaccine candidates, including efficacy levels, dosing regimens, storage requirements, prices, production capacities in 2021, and stocks reserved for low-income and middle-income countries. We use a traffic-light system to signal the potential contributions of each candidate to achieving global vaccine immunity, highlighting important trade-offs that policy makers need to consider when developing and implementing vaccination programmes. ...

Tight supply creates reluctance over federal vaccine sites OKLAHOMA CITY (AP) — The Biden administration's plan to open 100 vaccination sites by the end of the month was initially embraced by governors and health officials, who considered it a much needed... AP NEWS

OKLAHOMA CITY (AP) — The Biden administration’s plan to open 100 vaccination sites by the end of the month was initially embraced by governors and health officials, who considered it a much needed lifeline to get more Americans inoculated against the coronavirus.